An international team of researchers led by Professor Morris Brown FRS at Queen Mary University of London found that ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

In March, the company had received approval from the drug regulator to import and sell sodium zirconium cyclosilicate powder ...

The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...

AstraZeneca's new drug, baxdrostat, has successfully lowered blood pressure in a late-stage trial for treatment-resistant ...

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with ...

UK pharma major AstraZeneca today announced positive high-level results from the baxdrostat BaxHTN Phase III trial in ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...

The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstaZeneca shares with a ...